Chennai, Tamil Nadu, India, September 2025 — Manikandan S A (SAM) has been appointed as Managing Director at Grandix Pharmaceuticals, Ltd. In this new role, he will spearhead the company’s growth strategy, product innovation, and market expansion, building on his long association with the pharmaceutical industry and his proven expertise in leadership, brand-building, and business transformation.
Manikandan brings a rich legacy of over three decades in the pharmaceutical sector. He was earlier the Co-Founder, Co-Promoter, and Managing Director of Grandix Pharmaceuticals, Ltd., where he played a pivotal role in building the organization from its inception in 1996. Starting with just a handful of employees, he scaled the company into a formidable force, introducing blockbuster brands such as ReNerve, which became a market leader in its category, and developing novel drug delivery products for diabetes, hypertension, and hypercholesterolemia. Under his leadership, Grandix consistently delivered strong growth, high profitability, and significant shareholder value.
In parallel, he served as Chief Mentor at Olympus Therapeutics, a niche brand marketing organization in infertility, IVF, and gynecology specialties, where he guided the team in launching first-of-its-kind brands and positioning the company for accelerated growth. His leadership was marked by a collective, collaborative, and concept-driven approach that nurtured both people and brands.
Previously, he was associated with Strides Arcolab Ltd. as CEO – Global Brands, where he managed Indian and international business portfolios, built a strong product pipeline, and redefined corporate strategy for pharmaceutical and nutraceutical divisions. He was also the Co-Founder and Director at Huclin Research Ltd., a contract research organization offering clinical operations, data management, pharmacovigilance, and biostatistics services.
Manikandan’s early career included leadership roles at Abbott (earlier Solvay & Duphar) and Ranbaxy, where he built strong sales teams, drove performance, and gained a deep understanding of the pharmaceutical market at the grassroots level.
An accomplished academic, Manikandan holds a PhD in Management from SRM Institute of Science and Technology, where he presented research on corporate strategy, mergers, and acquisitions in Indian pharmaceutical companies. He also holds an MBA in Marketing from the National Institute of Business Management. His thought leadership in brand-building, M&A strategy, and performance turnarounds has been recognized widely across the industry.
With his return to Grandix as Managing Director, Manikandan is expected to drive a renewed phase of growth and innovation, reinforcing the company’s standing as a respected player in India’s pharmaceutical landscape.
About Grandix Pharmaceuticals, Ltd.
Grandix Pharmaceuticals, Ltd., founded in 1996 and headquartered in Chennai, India, is a pharmaceutical manufacturing company with a strong legacy of creating innovative therapies and building market-leading brands. Known for its pioneering products in neurology, pain management, gynecology, and lifestyle disorders, Grandix has consistently focused on patient-centric innovation and operational excellence. With a strong emphasis on research, compliance, and quality, the company continues to make significant contributions to India’s pharmaceutical sector.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
